Assembly Biosciences Cash on Hand 2010-2024 | ASMB

Assembly Biosciences cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Assembly Biosciences Annual Cash on Hand
(Millions of US $)
2023 $130
2022 $92
2021 $147
2020 $216
2019 $274
2018 $218
2017 $120
2016 $53
2015 $68
2014 $29
2013 $27
2012 $20
2011 $37
2010 $15
2009 $0
Assembly Biosciences Quarterly Cash on Hand
(Millions of US $)
2024-06-30 $109
2024-03-31 $113
2023-12-31 $130
2023-09-30 $46
2023-06-30 $60
2023-03-31 $73
2022-12-31 $92
2022-09-30 $109
2022-06-30 $117
2022-03-31 $123
2021-12-31 $147
2021-09-30 $181
2021-06-30 $199
2021-03-31 $215
2020-12-31 $216
2020-09-30 $238
2020-06-30 $227
2020-03-31 $249
2019-12-31 $274
2019-09-30 $157
2019-06-30 $174
2019-03-31 $194
2018-12-31 $218
2018-09-30 $234
2018-06-30 $93
2018-03-31 $109
2017-12-31 $120
2017-09-30 $66
2017-06-30 $76
2017-03-31 $91
2016-12-31 $53
2016-09-30 $59
2016-06-30 $64
2016-03-31 $58
2015-12-31 $68
2015-09-30 $66
2015-06-30 $71
2015-03-31 $96
2014-12-31 $29
2014-09-30 $18
2014-06-30 $21
2014-03-31 $24
2013-12-31 $27
2013-09-30 $32
2013-06-30 $33
2013-03-31 $37
2012-12-31 $20
2012-09-30 $24
2012-06-30 $29
2012-03-31 $31
2011-12-31 $37
2011-09-30 $53
2011-06-30 $11
2011-03-31 $14
2010-12-31 $15
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.107B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00